A recent study published at The Lancet medical journal analyses the evolution of pneumococcal disease caused by S. pneumoniae serotype 3 over the last three decades in Spain

It concludes that paediatric vaccination has not had the expected effect of group protection in adults against this serotype of the disease, so that this segment of the population will need direct protection through vaccination. While a decrease in the overall incidence of invasive pneumococcal disease (IPD) was observed, that caused by serotype 3 remained stable.

This form of the disease is associated with high mortality and, although serotype 3 is included in the PCV13 vaccine, its incidence remains high. In fact, according to the clinical data presented in the study, the mortality rate in the first 30 days was high (32.4%). Although it decreased to 16.7% over the course of the study, this highlights the importance of both vaccination and early detection and diagnosis to avoid the most serious complications of the disease (meningitis and pneumonia among others), as well as its transmission through individual-to-individual transmission by inhalation of respiratory droplets infected with the pathogens.

OPERON has three products for the detection of S.pneumoniae:

The Simple/Stick Strep pneumo and Simple/Stick Strep pneumo-Legio rapid tests (combo test that also includes L. pneumophila detection on the same strip) are performed on human urine samples and shorten patient management times, crucial to avoid both complications of the disease and the spread of the disease.

The S.pneumoStrip molecular diagnostic test for the identification of up to 76 serotypes of S.pneumoniae (including serotype 3), key for epidemiological studies such as the one mentioned in the article or for studying antibiotic resistance.

Do you like this article?

Share on Facebook
Share on Twitter
Share on Linkedin
Share on Pinterest

You may also be interested in